Morepen Laboratories Share Price (MOREPENLAB)

Morepen Laboratories Limited is a pharmaceutical company based in India that develops and markets formulation products in numerous therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic, and neuropsychiatry. Their products include Loratadine Montelukast Sodium, Atorvastatin Calcium and Sultamicillin, along with new entries such as Kilbac Ducal, D Aclomore and Montelast-L. It currently has three state-of-the-art manufacturing plants in Himachal Pradesh, India, with the main plant in Parwanoo being USFDA-approved for Loratadine production. The company was established in 1984 and since then has filed 14 patents, including an international one on a new amorphous form of Lipitor Atorvastatin. Expansion plans from 1992-1993 saw the installation of bulk drugs from 162 MT to 245 MT and the launch of two new molecules – Ketrolac, Tromethamine and Omeprazole. In 1995-1996, the company increased bulk drug installation from 305 MT to 469 MT and launched Loratadine and Cisapride. The year 1996-1997 saw the commencement of their own formulation unit, while they filed an international patent on a new amorphous form of Atorvastatin, world’s largest selling drug in 2000-2001. In 2001-2002, their drug and drug intermediate installation reached 1251 MT, with the launch of a number of contemporary lifestyle and self-medication products. Their joint venture with DiaMed AG of Switzerland was among the highlights of the year 2004-2005, while 2006-2007 saw them acquire fifty new prospective customers in Korea, Japan and Taiwan. The year 2007-2008 was marked by the company making tie-ups with several new business segments, along with marketing alliances with global players such as Immucor USA, Teco Medical Instruments, and In-Tech, INC.

Revenue: ₹465.85Cr as on March 2025 (Q4 FY25)
Net Profit: ₹20.31Cr as on March 2025 (Q4 FY25)
Listing date: 15 May, 1995
Chairperson Name: Sushil Suri